Ibudilast attenuates expression of behavioral sensitization to cocaine in male and female rats. (October 2016)
- Record Type:
- Journal Article
- Title:
- Ibudilast attenuates expression of behavioral sensitization to cocaine in male and female rats. (October 2016)
- Main Title:
- Ibudilast attenuates expression of behavioral sensitization to cocaine in male and female rats
- Authors:
- Poland, Ryan S.
Hahn, Yun K.
Knapp, Pamela E.
Beardsley, Patrick M.
Bowers, M. Scott - Abstract:
- Abstract: There are no FDA-approved pharmacotherapies for cocaine use disorder, indicating a need to identify novel reagents with therapeutic potential. Ibudilast is an anti-inflammatory glial attenuator and non-selective phosphodiesterase inhibitor currently undergoing clinical evaluations for methamphetamine, opiate, and alcohol abuse disorders. We previously showed that twice daily (b.i.d.) ibudilast reduces the development of methamphetamine sensitization in male mice. However, nothing is known about the ability of ibudilast to modulate the expression of sensitization that occurs after drug re-exposure during abstinence, effects on cocaine-mediated behaviors, or potentially sexually dimorphic effects. Male and female rats were administered cocaine for 7 days and expression of sensitization was assessed by cocaine challenge after 21 days abstinence. On test days, 15 mg/kg i. p. cocaine was evaluated, whereas 30 mg/kg was administered on intervening days. Lower test doses avoid competition of non-motor behaviors with locomotion. In all measures where sensitization was expressed, ibudilast (7.5 and 10 mg/kg, i. p., b. i.d. for 3 days and once on test day) reversed this behavior to levels seen after acute exposure, but not below. There were some intriguing sexually dimorphic effects that were not a function of estrous cycle. Specifically, distance travelled in the center of the test arena and rearing only sensitized in male rats, and ibudilast reversed these behaviors toAbstract: There are no FDA-approved pharmacotherapies for cocaine use disorder, indicating a need to identify novel reagents with therapeutic potential. Ibudilast is an anti-inflammatory glial attenuator and non-selective phosphodiesterase inhibitor currently undergoing clinical evaluations for methamphetamine, opiate, and alcohol abuse disorders. We previously showed that twice daily (b.i.d.) ibudilast reduces the development of methamphetamine sensitization in male mice. However, nothing is known about the ability of ibudilast to modulate the expression of sensitization that occurs after drug re-exposure during abstinence, effects on cocaine-mediated behaviors, or potentially sexually dimorphic effects. Male and female rats were administered cocaine for 7 days and expression of sensitization was assessed by cocaine challenge after 21 days abstinence. On test days, 15 mg/kg i. p. cocaine was evaluated, whereas 30 mg/kg was administered on intervening days. Lower test doses avoid competition of non-motor behaviors with locomotion. In all measures where sensitization was expressed, ibudilast (7.5 and 10 mg/kg, i. p., b. i.d. for 3 days and once on test day) reversed this behavior to levels seen after acute exposure, but not below. There were some intriguing sexually dimorphic effects that were not a function of estrous cycle. Specifically, distance travelled in the center of the test arena and rearing only sensitized in male rats, and ibudilast reversed these behaviors to levels seen after acute cocaine exposure. In females, center distance travelled was reduced below acute cocaine levels by 7.5 mg/kg ibudilast. Increased distance travelled in the center versus periphery is thought to model anxiolytic-like behavior due to increased predation risk. Taken together, these data suggest that the clinical evaluation of ibudilast could be extended to cocaine use disorder. Graphical abstract: Highlights: Ibudilast reversed expression of cocaine sensitization in female and male rats - 77/85 characters. Total distance and peripheral distance travelled were reversed in both sexes - 76/85 characters. Sexually dimorphic effects were observed for center distance travelled - 71/85 characters. No estrous cycle effect was observed - 35/85 characters. … (more)
- Is Part Of:
- Neuropharmacology. Volume 109(2016)
- Journal:
- Neuropharmacology
- Issue:
- Volume 109(2016)
- Issue Display:
- Volume 109, Issue 2016 (2016)
- Year:
- 2016
- Volume:
- 109
- Issue:
- 2016
- Issue Sort Value:
- 2016-0109-2016-0000
- Page Start:
- 281
- Page End:
- 292
- Publication Date:
- 2016-10
- Subjects:
- Cocaine -- Sensitization -- Sex -- Ibudilast -- AV411 -- MN-166
Cocaine HCl (PubChem CID: 656832) -- Ibudilast (PubChem CID: 3671)
Neuropsychopharmacology -- Periodicals
Autonomic Agents -- Periodicals
Neuropsychopharmacologie -- Périodiques
Neuropsychopharmacology
Periodicals
Electronic journals
615.78 - Journal URLs:
- http://www.sciencedirect.com/science/journal/00283908 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.neuropharm.2016.06.024 ↗
- Languages:
- English
- ISSNs:
- 0028-3908
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6081.517500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 821.xml